文献リスト

1) McCune WS, Shorb PE, Moscovitz H, et al. Endoscopic cannulation of the ampulla of Vater; a preliminary report. Ann Surg. 1968; 167: 752-5

2) 高木國夫, 他. 十二指腸ファイバースコピーによる逆行性総胆管および膵管造影の1例. 日医放会誌. 1969; 29: 590

3) 大井 至. Fiberduodenscope(FDS-Lb)による内視鏡的膵管造影. 日消会誌. 1969; 66: 880-3

4) Kawai K, Akasaka T, Hashimoto H, et al. Preliminary report on endscopical papillotomy. J Kyoto Pref Univ Med. 1973; 82: 353-5

5) 相馬 智, 立川 勲, 岡本安弘, 他. 内視鏡的乳頭切開術および遺残胆道結石摘出の試み—第1報—. Castroenterol Endosc. 1974; 16: 446-52

6) Classen M, Demling L. Endoscopiche sphinkteromie der Papilla Vateri und Stein-extraktion aus dem Ductus Choledochus. Dtsch Med Wochenschr. 1974; 99: 496-7

7) 金子榮藏, 他. 内視鏡的逆行性膵胆管造影検査(ERCP)の偶発症防止のための指針. 日本消化器内視鏡学会雑誌. 2000; 42: 2294-301

8) Johnson GK, Geenen JE, Johanson JF, et al. Evaluation of post-ERCP pancreatitis: Potential causes noted during controlled study of different contrast media. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1997; 46: 217-22

9) Sherman S, Hawes RH, Troiano FP, et al. Pancreatitis following bile duct sphincter of Oddi manometry: Utility of the aspirating catheter. Gastrointest Endosc. 1992; 38: 347-50

10) George S, Kulkarni AA, Stevens G, et al. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a metaanlysis. Dig Dis Sci. 2004; 49: 503

11) Sherman S. ERCP and endoscopic sphincterotomy-induced pancreatitis. Am J Gastroenterol. 1994; 89: 303-5

12) Ratani RS, Mills TN, Ainly CC, et al. Electrophysiological factors influencing endoscopic sphincterotomy. Gastrointest Endosc. 1999; 49: 43-52

13) Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc. 1991; 37: 383-93

14) Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996; 335: 909-18

15) Cheon YK, Cho KB, Watkins JL, et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc. 2007; 65: 385-93

16) Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998; 48: 1-10

17) Rabenstein T, Framke B, Martus P, et al. Patient-related risk factors for complications of endoscopic sphincterotomy: A prospective study (abstract). Gastrointest Endosc. 1999; 49: AB74

18) Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study. Am J Gastroenterol. 2001; 96: 417-23

19) Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study. Gastrointest Endosc. 2001; 54: 425-34

20) Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc. 2002; 56: 652-56

21) Christensen M, Matzen P, Schulze S, et al. Complications of ERCP: a prospective study. Gastrointest Endosc. 2004; 60: 721-31

22) Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: A prospective multicenter study. Am J Gastroenterol. 2006; 101: 139-47

23) Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy. 2007; 39: 793-801

24) Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol. 2009; 104: 31-40

25) Gottlieb K, Sherman S, Pezzi J, et al. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol. 1996; 91: 1553-7

26) Testoni PA, Bagnolo F, Caporuscio S, et al. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis. Am J Gastroenterol. 1999; 94: 1235-41

27) Testoni PA, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc. 2001; 53: 33-9

28) Kemppainen E, Hedstrom J, Puolakkainen P, et al. Increased serum trypsinogen 2 and trypsin 2-alpha 1 antitrypsin complex values identify endoscopic retrograde cholangiopancreatography induced pancreatitis with high accuracy. Gut. 1997; 41: 690-5

29) Kemppainen E, Hedstrom J, Puolakkainen P, et al. Urinary trypsinogen-2 test strip in detecting ERCP-induced pancreatitis. Endoscopy. 1997; 29: 247-51

30) Tympner F, Rosch W. Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP. Z Gastroenterol. 1982; 20: 688-93

31) Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004; 59: 606-13

32) Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: A multicenter randomized controlled trial. Gastrointest Endosc. 2002; 55: 470-5

33) Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc. 2007; 65: 624-32

34) Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas. 2008; 37: 445-8

35) 峯 徹哉. 内視鏡的乳頭括約筋切開術(EST)の偶発症とその対策. 消化器内視鏡. 1994; 6: 495-9

36) Freeman ML, Cuda NM. Prevention of Post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004: 59: 845-64

37) Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc. 1993; 39: 652-7

38) Sherman S, Earle DT, Bucksot L, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES)-induced pancreatitis？ A final analysis of a randomized prospective study [abstract]. Gastrointest Endosc. 1996; 43: A489

39) Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology. 1998; 115: 1518-24

40) Elton E, Howell DA, Parsons WG, et al. Endoscopic pancreatic sphincterotomy: indications, outcome, and a safe stentless technique. Gastrointest Endosc. 1998; 47: 240-9

41) Patel R, Tarnasky P, Hennessy WS, et al. Does stenting after pancreatic sphincterotomy reduce post-ERCP pancreatitis in patients with prior biliary sphincterotomy？ Preliminary results of a prospective randomized trial [abstract]. Gastrointest Endosc. 1999; 49: AB80

42) Vandervoort J, Soetikno RM, Montes H, et al. Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct. Gastrointest Endosc. 1999; 49: 322-7

43) Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc. 2001; 54: 209-13

44) Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy. 2002; 34: 280-5

45) Norton ID, Gostout CJ, Baron TH, et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc. 2002; 56: 239-43. 47: 240-9

46) Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis？ A prospective randomized study. Gastrointest Endosc. 2003; 57: 291-4

47) Catalano MF, Linder JD, Chak A, et al. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc. 2004; 59: 225-32

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp